Press Releases

GlobeNewswire, Inc.

PLAINVIEW, N.Y., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive medical products, today announced its...

GlobeNewswire, Inc.

Record Quarterly Revenue of $1.4 Million, Up 28% Year-over-Year; First-Half Revenue Up 26% compared to the corresponding period in 2025 Deliberate Investment in Building the U.S. Direct-Sales Foundation Aimed at Unlocking Significant Long Term...

GlobeNewswire, Inc.

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today it will report its financial results for the third quarter ended June 30, 2026 on Thursday, August...

GlobeNewswire, Inc.

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current quarter regarding potential...

GlobeNewswire, Inc.

Company Delivers 118% Q2 Revenue Growth, Reaffirms Full-Year 2026 Guidance of $12 Million (113% YoY Growth) FREDERICK, Md., Aug. 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and...

GlobeNewswire, Inc.

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized...

GlobeNewswire, Inc.

– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – Receives U.S. Notice of...

GlobeNewswire, Inc.

Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout...

GlobeNewswire, Inc.

1H 2026 revenue increased 9.2% Continued focus on identifying accretive commercial opportunities and controlling costs NEW PORT RICHEY, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”),...

GlobeNewswire, Inc.

Strong Resonance with Cities Interested in Buying Bond for Residents and City Workers, Coupled with Demonstrable Ability to Fund Growth While Being Sensitive to Dilution Net Loss Narrowed 28% and Operating Expenses Declined 41% Sequentially; Cash...

GlobeNewswire, Inc.

LOS ANGELES, Aug. 13, 2026 (GLOBE NEWSWIRE) -- via IBN — Nightfood Holdings, Inc. (OTCQB: NGTF), doing business as TechForce Robotics (the “Company”), today announced that its wholly owned subsidiary, TechForce Robotics, Inc. (“TechForce”), has...

GlobeNewswire, Inc.

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter...

GlobeNewswire, Inc.

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.

GlobeNewswire, Inc.

Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer...

GlobeNewswire, Inc.

SINGAPORE, Aug. 14, 2026 (GLOBE NEWSWIRE) -- JOYY Inc. (NASDAQ: JOYY) (“JOYY” or the “Company”), a global technology company, today announced that it plans to release its second quarter 2026 financial results after the U.S. market closes on August...

GlobeNewswire, Inc.

Significant progress against cost reduction efforts positions business for sustained success LanzaTech advancing towards world's first ISCC EU certification for recycled carbon fuels in China SKOKIE, Ill., Aug. 14, 2026 (GLOBE NEWSWIRE) --...

GlobeNewswire, Inc.

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with an update anticipated in...

GlobeNewswire, Inc.

HANGZHOU, China, Aug. 14, 2026 (GLOBE NEWSWIRE) -- UTStarcom (“UT,” “UTStarcom” or the “Company”) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today reported its unaudited financial results and a business update for the six...

GlobeNewswire, Inc.

Medical Segment Revenue Grows 231% Year-Over-Year Enters Strategic Distribution Agreement to Expand CompuFlo® Access Across VA and Department of Defense Health Systems Reaffirms 2026 Outlook for Double-Digit Revenue Growth, Including Significant...

GlobeNewswire, Inc.

LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and...